Stay updated on Pembrolizumab Maintenance in Unresectable Stage III NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Maintenance in Unresectable Stage III NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Maintenance in Unresectable Stage III NSCLC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Revision: v3.4.3 is now displayed on the page, replacing Revision: v3.4.2.
    Difference
    0.1%
    Check dated 2026-03-11T17:19:54.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added and the funding-status notice was removed, representing a minor site maintenance update that does not affect the trial details or user actions on the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-11T06:24:25.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Added a site-wide Notice about a lapse in government funding with directions to cc.nih.gov and opm.gov. Updated the page to Revision: v3.4.1, replacing v3.4.0.
    Difference
    0.4%
    Check dated 2026-02-04T05:15:42.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Minor editorial updates include capitalization tweaks for QC terminology, a new 'Show glossary' option, and a revision tag (v3.4.0) replacing the previous version.
    Difference
    0.2%
    Check dated 2026-01-28T03:30:45.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    Page revision updated from v3.3.3 to v3.3.4.
    Difference
    0.1%
    Check dated 2026-01-14T01:41:24.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    The page now includes an expanded Locations section with new study sites in Pordenone and Turin, updating where the trial is conducted. The footer item HHS Vulnerability Disclosure was removed (a minor change) and the revision updated to v3.3.3.
    Difference
    0.3%
    Check dated 2025-12-23T10:15:22.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Maintenance in Unresectable Stage III NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Maintenance in Unresectable Stage III NSCLC Clinical Trial page.